{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:08:47Z","timestamp":1778692127626,"version":"3.51.4"},"reference-count":0,"publisher":"Canadian Society of Healthcare-Systems Pharmacy","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can J Hosp Pharm"],"abstract":"<jats:p>Background: Hospital admissions for patients living with opioid use disorder (OUD) are increasing, and patient-centred interventions are required to maximize the impact of OUD treatment. It is important to continue pharmacotherapy for hospitalized patients with OUD to prevent withdrawal and self-directed discharge.\nObjectives: The primary objective was to identify the proportion of any OUD pharmacotherapy administered more than 24 hours after hospital presentation. Secondary objectives included determining the proportion of home OUD regimens ordered during transitions of care, the incidence of OUD pharmacotherapy initiation during hospitalization, and the incidence of deleterious events.\nMethods: A retrospective chart review was conducted for 100 adult medicine patients with OUD and existing OUD pharmacotherapy or newly initiated opioid agonist therapy seen in hospital between November 2023 and June 2024.\nResults: Of the 74 patients on prior OUD pharmacotherapy, 64 (86%) received a dose of any OUD pharmacotherapy within 24 hours of hospital presentation. In addition, 54 (73%) of these patients did not have their full home OUD regimens ordered on admission, and for 20 (37%) of these 54 patients, changes to home regimens lacked documented justification. Intentional changes to home regimens on admission were most often due to opioid toxicity events and altered level of consciousness. Deleterious outcomes were common and included self-directed discharge and code white events.\nConclusions: Most patients with existing OUD pharmacotherapy received doses of any OUD pharmacotherapy within 24 hours of presentation to hospital. Gaps in care were identified in the continuation of home OUD pharmacotherapy regimens, especially among patients with multiagent regimens.\nKeywords: continuity of patient care; opioid-related disorders; analgesics, opioid; hospitalization; pharmacy service, hospital\nR\u00c9SUM\u00c9\nContexte : Les admissions de patients vivant avec un trouble li\u00e9 \u00e0 la consommation d\u2019opio\u00efdes (TCO) \u00e0 l\u2019h\u00f4pital sont en augmentation, et des interventions centr\u00e9es sur le patient sont n\u00e9cessaires pour maximiser l\u2019efficacit\u00e9 du traitement pour celui-ci. Il est important de poursuivre la pharmacoth\u00e9rapie des patients hospitalis\u00e9s atteints d\u2019un TCO afin de pr\u00e9venir les sympt\u00f4mes de sevrage et les cong\u00e9s autodirig\u00e9s.\nObjectifs : L\u2019objectif principal consistait \u00e0 identifier la part des patients recevant une pharmacoth\u00e9rapie en raison d\u2019un TCO plus de 24 heures apr\u00e8s leur admission \u00e0 l\u2019h\u00f4pital. Les objectifs secondaires comprenaient la d\u00e9termination de la part de traitements \u00e0 domicile prescrits pour le TCO lors des transitions de soins, l\u2019incidence des initiations de pharmacoth\u00e9rapie pour le TCO pendant l\u2019hospitalisation et l\u2019incidence d\u2019\u00e9v\u00e9nements n\u00e9fastes.\nM\u00e9thodologie : Une revue r\u00e9trospective des dossiers de 100 patients adultes en m\u00e9decine trait\u00e9s \u00e0 l\u2019h\u00f4pital a \u00e9t\u00e9 r\u00e9alis\u00e9e entre novembre 2023 et juin 2024. Ces patients \u00e9taient atteints d\u2019un TCO et recevaient soit une pharmacoth\u00e9rapie existante pour celui-ci, soit un traitement par agoniste opio\u00efde nouvellement initi\u00e9.\nR\u00e9sultats : Parmi les 74 patients recevant d\u00e9j\u00e0 une pharmacoth\u00e9rapie pour le TCO, 64 (86 %) ont re\u00e7u une dose de traitement dans les 24 heures suivant leur admission \u00e0 l\u2019h\u00f4pital. De plus, l\u2019int\u00e9gralit\u00e9 du traitement \u00e0 domicile pour le TCO n\u2019avait pas \u00e9t\u00e9 command\u00e9e au moment de l\u2019admission pour 54 de ces patients (73 %). Pour 20 (37%) de ces 54 patients, les modifications apport\u00e9es aux traitements \u00e0 domicile n\u2019\u00e9taient pas accompagn\u00e9es d\u2019une justification \u00e9crite. Les modifications intentionnelles des traitements \u00e0 domicile au moment de l\u2019admission \u00e9taient le plus souvent dues \u00e0 des \u00e9v\u00e9nements de toxicit\u00e9 aux opio\u00efdes ou \u00e0 une alt\u00e9ration de l\u2019\u00e9tat de conscience. Les issues n\u00e9fastes \u00e9taient fr\u00e9quentes; elles comprenaient les cong\u00e9s autodirig\u00e9s et les \u00e9v\u00e9nements de type \u00ab code blanc \u00bb.\nConclusions : La majorit\u00e9 des patients d\u00e9j\u00e0 sous pharmacoth\u00e9rapie pour le TCO ont re\u00e7u une dose de traitement dans les 24 heures suivant leur admission \u00e0 l\u2019h\u00f4pital. Des lacunes dans la prise en charge ont \u00e9t\u00e9 identifi\u00e9es dans la continuit\u00e9 des traitements \u00e0 domicile pour le TCO, en particulier chez les patients suivant des r\u00e9gimes combinant plusieurs agents.\nMots-cl\u00e9s : continuit\u00e9 des soins aux patients, troubles li\u00e9s \u00e0 la consommation d\u2019opio\u00efdes, analg\u00e9siques opio\u00efdes, hospitalisation, service de pharmacie hospitali\u00e8re<\/jats:p>","DOI":"10.4212\/cjhp.3907","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:08:32Z","timestamp":1778688512000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluating Opioid Agonist Therapy and Safer Supply Medications during Transitions of Care for Medical Inpatients with Opioid Use Disorder: A Retrospective Chart Review"],"prefix":"10.4212","volume":"79","author":[{"given":"Yousif","family":"Jaheinsha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Shea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"My-Linh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2732","published-online":{"date-parts":[[2026,5,13]]},"container-title":["Canadian Journal of Hospital Pharmacy"],"original-title":[],"link":[{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3907\/5878","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3907\/5882","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3907\/5878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:08:33Z","timestamp":1778688513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/view\/3907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4,8]]}},"URL":"https:\/\/doi.org\/10.4212\/cjhp.3907","relation":{},"ISSN":["1920-2903","0008-4123"],"issn-type":[{"value":"1920-2903","type":"electronic"},{"value":"0008-4123","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"article-number":"e3907"}}